The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Top Cited Papers
- 1 February 2003
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 52 (2) , 380-386
- https://doi.org/10.2337/diabetes.52.2.380
Abstract
The intestinally derived hormone glucagon-like peptide 1 (GLP-1) (7-36 amide) has potent effects on glucose-mediated insulin secretion, insulin gene expression, and β-cell growth and differentiation. It is, therefore, considered a potential therapeutic agent for the treatment of type 2 diabetes. However, the dose-response relationship between GLP-1 and basal and glucose-stimulated prehepatic insulin secretion rate (ISR) is currently not known. Seven patients with type 2 diabetes and seven matched nondiabetic control subjects were studied. ISR was determined during a graded glucose infusion of 2, 4, 6, 8, and 12 mg · kg−1 · min−1 over 150 min on four occasions with infusion of saline or GLP-1 at 0.5, 1.0, and 2.0 pmol · kg−1 · min−1. GLP-1 enhanced ISR in a dose-dependent manner during the graded glucose infusion from 332 ± 51 to 975 ± 198 pmol/kg in the patients with type 2 diabetes and from 711 ± 123 to 2,415 ± 243 pmol/kg in the control subjects. The β-cell responsiveness to glucose, expressed as the slope of the linear relation between ISR and the glucose concentration, increased in proportion to the GLP-1 dose to 6 times relative to saline at the highest GLP-1 dose in the patients and 11 times in the control subjects, but it was 3 to 5 times lower in the patients with type 2 diabetes compared with healthy subjects at the same GLP-1 dose. During infusion of GLP-1 at 0.5 pmol · kg−1 · min−1 in the patients, the slope of ISR versus glucose became indistinguishable from that of the control subjects without GLP-1. Our results show that GLP-1 increases insulin secretion in patients with type 2 diabetes and control subjects in a dose-dependent manner and that the β-cell responsiveness to glucose may be increased to normal levels with a low dose of GLP-1 infusion. Nevertheless, the results also indicate that the dose-response relation between β-cell responsiveness to glucose and GLP-1 is severely impaired in patients with type 2 diabetes.Keywords
This publication has 34 references indexed in Scilit:
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.Journal of Clinical Investigation, 1998
- Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humansActa Physiologica Scandinavica, 1997
- Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 1997
- Secretion of the Incretin Hormones Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide Correlates with Insulin Secretion in Normal Man Throughout the DayScandinavian Journal of Gastroenterology, 1996
- Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations.Journal of Clinical Investigation, 1994
- Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrationsJournal of Clinical Endocrinology & Metabolism, 1993
- Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)Nature, 1993
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993
- Banting lecture 1990. Beta-cells in type II diabetes mellitusDiabetes, 1991
- Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus RevisitedPathology and Immunopathology Research, 1985